Replies to post #222687 on Amarin Corp Plc (AMRN)

[Biobillionair]

Vascepa is being reviewed by Endocrinologic and Metabolic Drugs Advisory Committee, here:

https://www.fda.gov/advisory-committees/november-14-2019-meeting-endocrinologic-and-metabolic-drugs-advisory-committee-meeting-announcement

Today FDA gave notice for another drug to be reviewed by Cards & Renal, not related to Vascepa or Amarin.

Here:
https://www.regulations.gov/document?D=FDA-2019-N-4986-0001

Agenda: The committee will be asked to discuss new drug application (NDA) 022034, for vernakalant HCl solution, for intravenous injection, submitted by Correvio International Sàrl, for the proposed indication of rapid conversion of recent onset atrial fibrillation to sinus rhythm for non-surgery patients: Atrial fibrillation ≤7 days duration, and for post-cardiac surgery patients: Atrial fibrillation ≤3 days duration.

Got it?

BB